Alliances
Israel-based drug maker Compugen Ltd. and pharma giant AstraZeneca have teamed up to develop bi-specific and multi-specific immuno-oncology antibody products.
MediciNova announced that its Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.
In an initial public offering, Unum Therapeutics snagged nearly $70 million to fund its antibody-coupled T-cell receptor technology.
Celgene and bluebird bio have inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen (BCMA) CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).
Homology Medicines has raised $144 million in an initial public offering of stock.
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.
Regeneron Pharmaceuticals and Alnylam Pharmaceuticals signed a collaboration deal to identify RNAi therapies for nonalcoholic steatohepatitis (NASH) and other possibly related liver diseases.
Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases.
PRESS RELEASES